PARTEQ innovationsResearch & InventorsIndustry & Investors

[technology opportunities: LIFE SCIENCES]


Industry & InvestorsCompanies Products Venture Funds
Technology Opportunities: Life Sciences Physical Sciences

> Anesthetic-Eluting Polymethylmethacrylate (PMMA)
Researchers at Queen’s University have developed anesthetic-eluting PMMA for applications in localized pain management.

> Bioinformatics and Data Mining: software and algorithms
GeneLinker™ gene espression analysis software offers a powerful set of analysis and visualization tools for the exploration of gene expression data. Proprietary algorithms such as SLAM (SubLinear Association Mining) and IBIS (Integrated Bayesian Inference System) provide an efficient way to charcterize higher-order correlations among objects in a multidimensional dataset.


> Biodegradable Elastomer

A patented method of formulating resorbable, drug-eluting elastomers from clinically accepted monomers, such as D,L-lactide and ε-caprolactone.

> Canine Factor VIII Gene, Protein and Use
Technology providing methods useful during diagnosis of a canine Factor VIII deficiency-dependent bleeding disorder, and methods for treating a canine afflicted with such a disorder.

> DETECTS - Software for Identifying Circulatory Emboli

Researchers at Queen’s University have developed DETECTS -- Detection of Emboli using
Trans-esophageal Echocardiography for Counting, Total volume, and Size estimation. This software tool accurately measures flow rates of emboli in the ascending aorta while simultaneously providing quantitative data on size, volume and count.

> Hydrogel – Calcium Phosphate Linking Technology

A novel method of covalently binding hydrogels to calcium phosphate-based surfaces, thus, enabling the production of MACI-based osteochondral implants for use in cartilage repair.

> HyperSpace™ Helmet for Detecting Eye Movement
Apparatus for diagnosing a neurological disorder in a subject by detecting the subject's eye movement, allowing children with ADHD to be diagnosed and medication optimized.

 

> Kinarm™ - Mechanical Linkage to Study Multi-Joint Movements
Robotic exoskeleton that can both sense and modify the mechanics of multi-joint movements. Researchers can use this device to examine a range of questions on motor coordination and learning. Development of a clinical assessment tool is underway.

 

> Mammalian Sperm Proteins
Protein identified at Queen's that may play a critical role in the activation of the oocyte, with possible applications in human fertilization and contraception methods.

 

> Methods of Treating a CNS Disorder Using N,N-Dichlorinated Amino Acids and Derivatives
Compounds and methods for the synthesis of chlorinated amino acids for treatment of central nervous system (CNS) disorders including epilepsy and Alzheimer's.

> Monoclonal Antibodies to Baculovirus Proteins

Suite of monoclonal antibodies directed to baculovirus proteins, produced in mouse hybridoma cell lines, isolated and characterized.

 

> Multi-Drug Resistant Protein (MRP) Technology
Queen's University researchers Drs. Susan Cole and Roger Deeley were the first to clone the human Multi-drug Resistance Protein (MRP) following their 1992 discovery of the gene encoding for Multidrug Resistance Proteins (MRP).

 

> NO-Chimera Drugs & NO-Mimetic Therapeutic Approaches to Neurological Disorders including Alzheimer’s Disease

A large proprietary library of novel nitrates and NO-chimera drugs have been developed and are extensively protected by patents that cover novel composition and methods of preparation and use including in neurological disorders.

> Optical 3-D Exophthalmometer

A cost-effective, non-contact, non-ionizing exophthalmometer that uses
novel image-based rendering algorithms to construct a 3D computer model of the anterior
surface of the eye and the surrounding soft tissue of the face.

> Porphyrin Derivatives for Cancer Treatment
New class of porphyrin derivatives having both chemotherapeutic and photosensitizing activity.

 

> Protease Mediated Drug Delivery
Method of delivering cytotoxic drugs in high concentrations to maximize the amount of the cytotoxic agent taken up by malignant cells while minimizing toxicity to surrounding normal tissue.

 

> Proteoglycan Antagonists

A novel method for producing homogenous cyclodextran derivatives which have been showed to inhibit nerve process growth (neurite growth) are available for license.

> Recombinant r-Lp(a)
A novel method for producing recombinant lipoprotein A of specific sizes for research and clinical applications, including the development of diagnostic kits is available for license.

 

A fixed-bearing total knee system that employs an innovative bearing surface design to guide the motion of the joint in both flexion and extension and to attain normal kinematics in deep knee bending without the use of an intercondylar cam/post.

Copyright 2004 PARTEQ innovations - 613.533.2342info@parteqinnovations.comSitemapQueen's University